Forgot your password?

Forgot your username?

Thrombotech Biotech Specialty Pharma

, Israel
Click for website
Research Sector Biotech Specialty Pharma
Summary Description Thrombolytic Agent for Stroke Therapy

Click here for Financial Data KeywordsCardiology, Neurology, Regenerative Medicine. Ischemia, Stroke, Acute Myocardial Infarction, Pulmonary Embolism, Peripheral Arterial and Venous Occlusion, Thrombosis.


Thrombotech is developing innovative peptides that can address tPA unmet needs extending its therapeutic time window and reducing its adverse side effects.......view more

Products / Services

The first lead compound of Thrombotech is a peptide that when combined together with virtually every thrombolytic agent existing today (e.g., Urokinase, Alteplase) Retavase, TNKase) can increase its P......view more

Technology / Differentiation

Thrombotech has developed a distinctive lead compound to be used as safer thrombolytic agents: a Plasminogen Activator Inhibitor-1 (PAI-1) derived peptide. Thrombotech's animal studies (3 different sp...view more

Market / Customers

Approximately 750,000 patients suffer new ischemic strokes annually in the USA, about 150,000 of who die as a consequence. Worldwide, the incidence of stroke is estimated to be 2-2.5 per thousand, res......view more


Thrombotech has licensed and owns various patents / patent applications for the complex technology and the thrombolytic use of its lead peptide. GMP production of the peptide, further toxicity tests, ...view more